These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 37584249)
1. Sotatercept as a next-generation therapy for pulmonary arterial hypertension: insights from the STELLAR trial. Kopeć G Cardiovasc Res; 2023 Dec; 119(16):e155-e157. PubMed ID: 37584249 [No Abstract] [Full Text] [Related]
2. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. Hoeper MM; Badesch DB; Ghofrani HA; Gibbs JSR; Gomberg-Maitland M; McLaughlin VV; Preston IR; Souza R; Waxman AB; Grünig E; Kopeć G; Meyer G; Olsson KM; Rosenkranz S; Xu Y; Miller B; Fowler M; Butler J; Koglin J; de Oliveira Pena J; Humbert M; N Engl J Med; 2023 Apr; 388(16):1478-1490. PubMed ID: 36877098 [TBL] [Abstract][Full Text] [Related]
3. Sotatercept for the Treatment of Pulmonary Arterial Hypertension. Humbert M; McLaughlin V; Gibbs JSR; Gomberg-Maitland M; Hoeper MM; Preston IR; Souza R; Waxman A; Escribano Subias P; Feldman J; Meyer G; Montani D; Olsson KM; Manimaran S; Barnes J; Linde PG; de Oliveira Pena J; Badesch DB; N Engl J Med; 2021 Apr; 384(13):1204-1215. PubMed ID: 33789009 [TBL] [Abstract][Full Text] [Related]
4. Unsolved Issues on Beneficial Effects of Combination Therapy With Sotatercept in Pulmonary Arterial Hypertension. Benincasa G; Strozziero MG; Trama U; Napoli C Heart Lung Circ; 2024 Jan; 33(1):12-13. PubMed ID: 38040502 [No Abstract] [Full Text] [Related]
5. Sotatercept for pulmonary arterial hypertension: something old and something new. Rubin LJ; Naeije R Eur Respir J; 2023 Jan; 61(1):. PubMed ID: 36609525 [No Abstract] [Full Text] [Related]
6. Population Health Model Predicting the Long-Term Impact of Sotatercept on Morbidity and Mortality in Patients with Pulmonary Arterial Hypertension (PAH). McLaughlin V; Alsumali A; Liu R; Klok R; Martinez EC; Nourhussein I; Bernotas D; Chevure J; Pausch C; De Oliveira Pena J; Lautsch D; Hoeper MM Adv Ther; 2024 Jan; 41(1):130-151. PubMed ID: 37851297 [TBL] [Abstract][Full Text] [Related]
7. Sotatercept for Pulmonary Arterial Hypertension in the Inpatient Setting. Torbic H; Tonelli AR J Cardiovasc Pharmacol Ther; 2024; 29():10742484231225310. PubMed ID: 38361351 [TBL] [Abstract][Full Text] [Related]
8. Is sotatercept, which traps activins and growth differentiation factors, a new dawn in treating pulmonary arterial hypertension (PAH)? Doggrell SA Expert Opin Biol Ther; 2023; 23(7):589-593. PubMed ID: 37269300 [TBL] [Abstract][Full Text] [Related]
9. The Impact of Immunogenicity on the Pharmacokinetics, Efficacy, and Safety of Sotatercept in a Phase III Study of Pulmonary Arterial Hypertension. Liao K; Mackenzie H; Ait-Oudhia S; Manimaran S; Zeng Y; Akers T; Yun T; de Oliveira Pena J Clin Pharmacol Ther; 2024 Mar; 115(3):478-487. PubMed ID: 38012534 [TBL] [Abstract][Full Text] [Related]
10. Effects of sotatercept on lung diffusion capacity and blood gases in patients with pulmonary arterial hypertension. Olsson KM; Fuge J; Park DH; Kamp JC; Brod T; Harrigfeld B; Schupp JC; Hoeper MM Eur Respir J; 2023 Aug; 62(2):. PubMed ID: 37474157 [No Abstract] [Full Text] [Related]
11. Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension. Joshi SR; Liu J; Bloom T; Karaca Atabay E; Kuo TH; Lee M; Belcheva E; Spaits M; Grenha R; Maguire MC; Frost JL; Wang K; Briscoe SD; Alexander MJ; Herrin BR; Castonguay R; Pearsall RS; Andre P; Yu PB; Kumar R; Li G Sci Rep; 2022 May; 12(1):7803. PubMed ID: 35551212 [TBL] [Abstract][Full Text] [Related]